

# 3<sup>RD</sup> ANZ BIOLOGICS FESTIVAL 2025

## Post-Event Report

4th – 5th February 2025  
The Crown Promenade Melbourne, Australia

## THANK YOU TO OUR 2025 SPONSORS

### PLATINUM SPONSOR

**SARTORIUS**

### SILVER SPONSORS

**Pf** **Pfanzstiehl**  
**MERCK**

### ASSOCIATE SPONSORS

**BioOra**  
**FUJIFILM**

### CRO SPONSOR

**IQVIA**  
BIOTECH

### EXHIBITORS

ProBio **SGS** **ROQUETTE** **ALMAC** **novachem** **BIOSYSTEMS** **Acro** **cytiva**  
**VFV** **pharmadule** **QuickSTAT** **BioTools** **COPURE**  
A Morimatsu Group Company A Kuehne+Nagel Company Innovative Tools for Life Sciences FILTRATION

### ADVERTISERS

**FUJIFILM**  
**Diosynth**  
biotechnologies  
**BIOCYTOGEN** **BIOMICE**

### SUPPORTING PARTNERS

**BioPharma** **Life Sciences** **MEDTECH**  
Asia Review **OUTLOOK**

# TABLE OF CONTENTS

- Message from the Organizer
- Summary - ANZ Biologics Festival 2025
- Agenda At A Glance
- 2025 Speakers
- 5 Most popular Sessions
- Attendee Breakdown
- Attendee List
- Save the Dates
- 2025-2026 EU, US, & APAC Event Calendar
- All IMAPAC Products & Services
- About IMAPAC

## Follow Us!

 **LinkedIn:**  
<https://www.linkedin.com/company/imapac-pte-ltd>

 **Youtube:**  
<https://www.youtube.com/channel/UCdZUHRMcFpfYhUqkw41giew>

 **Twitter:**  
<https://twitter.com/imapac>



Dr. Angelo Perani  
Chief Scientific Officer, Neuclone

"It was a great success by the presentations of high caliber and relevance and by the networking possibilities."



Diane Finley  
Business Development Manager, Cytiva

"3rd ANZ Biologics Festival 2025 was a great event with a mix of speakers/topics from Protein to CAR-T and EV's to mRNA."



Hiroshi Sato  
Director of Marketing Operations,  
FUJIFILM Diosynth Biotechnologies  
Japan

"Good quality of attendees combined with the organizer's hospitality, leading to identifying a good number of sales prospects for our service offerings."



Helen Bazgalovski  
Head of Sales, Merck Life Science Pty Ltd

"This year's Biologics conference was valuable for getting up to speed with the developments in cell & gene therapy and the mRNA ecosystem. For suppliers and service providers, it was important to understand the gaps and challenges the industry faces to allow us to develop solutions in partnership and contribute to progressing the industry."



# MESSAGE FROM THE ORGANIZER



We are deeply grateful to all our partners for their support in making the **ANZ Biologics Festival 2025** a huge success. As part of IMAPAC's commitment to better serving all event stakeholders, we bring you the **post-conference report** for the show.

The purpose of this report is to provide you with detailed insights into the **2025 event**. It will also help all our partners measure the ROI of their participation. The **Australia Biologics Festival 2025** was held from **4th to 5th February** at **Crown Promenade Melbourne**, where attendees gained access to expert advice, discussions, and case studies on the booming opportunities in Australia's biologics industry.

The event attracted **world-class expert speakers and industry leaders**. We received valuable feedback from participants, which we deeply appreciate. A high percentage of attendees found the event to be **informative, need-oriented, and an excellent platform for networking with the right people**.

We are confident in expanding the event into an **even larger and better** one in **2026** by incorporating all the feedback received. We look forward to hosting the show once again next year!

**Thank you to all our partners once again for making the event a true success!**

Yours Sincerely,  
IMAPAC





# SUMMARY

## 3<sup>RD</sup> ANZ BIOLOGICS FESTIVAL 2025



240+  
ATTENDEES



92  
COMPANIES



51  
EXPERT SPEAKERS



2  
DAYS OF  
NETWORKING





# SPEAKERS 2025

## Advisory Board Members



**Nikolai Petrovsky,**  
*Chief Executive Officer,*  
Vaxine, Australia



**John Power,**  
*Senior Director,*  
BioNTech SE, Australia

## Speakers



**Rebecca Skinner,**  
*Director, Research and Industry  
Development, mRNA Victoria,  
Government of Victoria, Australia*



**Ellen Otte,**  
*Director,*  
CSL, Australia



**Mathew Adams,**  
*Senior Evaluator – Biological Science  
Section, Scientific Evaluation Branch,  
Therapeutic Goods Administration,  
Australia*



**Michael Baker,**  
*Chief Executive Officer &  
Managing Director,*  
Arovella Therapeutics, Australia



**Greg Troiano,**  
*Chief Manufacturing Officer,  
mRNA CoE, Sanofi, US*



**John Power,**  
*Senior Director,*  
BioNTech SE, Australia



**Jolanta Airey,**  
*Chief Medical Officer,*  
Cynata Therapeutics, Australia



**Rebecca McQualter,**  
*Chief Executive Officer,*  
Chimeric Therapeutics, Australia



**Jerry Kanellos,**  
*Chief Scientific Officer,*  
Immuron, Australia



**Gisela Mautner,**  
*Chief Executive Officer and  
Managing Director,*  
Noxopharm, Australia



**Carolyn Tucek-Szabo,**  
*Senior Director, Global Regulatory  
Sciences Lead - Australia/NZ;  
Policy & Liaison - SE Asia,  
Moderna, Australia*



**Tim Oldham,**  
*Chief Executive Officer &  
Managing Director,*  
AdAlta, Australia



**Nicholas Huntington,**  
*Co-founder & Chief Scientific Officer,  
oNko-Innate, Director of Research,  
Cancer Immunology,  
Monash University, Australia*



**Larisa Chisholm,**  
*Chief Operating Officer,*  
Denteric, Australia



**Marco Herold,**  
*Chief Executive Officer, Olivia  
Newton-John Cancer Research  
Institute, Head, School of Cancer  
Medicine, La Trobe University,  
Honorary Professorial Fellow,  
University of Melbourne, NHMRC  
Investigator, Australia*

# SPEAKERS 2025

## Speakers



**Jane Oliaro,**  
*Chief Scientist,  
Peter MacCallum Cancer  
Centre, Australia*



**Craig Newton,**  
*Executive Director & Founder,  
VivaZome Therapeutics, Australia*



**Richard Berry,**  
*Vice President, Biologics &  
Drug Discovery,  
oNKO-innate, Australia*



**Jennifer Short,**  
*Director,  
Monash Centre for Advanced mRNA  
Medicines Manufacturing and  
Workforce Training, Australia*



**Cheng-Yi Jerry Kuo,**  
*Vice General Manager,  
UWELL Biopharma, Taiwan*



**Jamie Triccas,**  
*Deputy Director, Sydney Infectious  
Diseases Institute, Infection,  
Immunity and Inflammation Theme,  
School of Medical Sciences, Faculty of  
Medicine and Health,  
The University of Sydney, Australia*



**Ian Nisbet,**  
*Chief Operating Officer,  
Cartherics, Australia*



**Silviu Itescu,**  
*Chief Executive Officer,  
Mesoblast, Australia*



**Ilya Vensky,**  
*Co-founder and Chief Executive Officer,  
Helico Bio, New Zealand*



**Deborah Rathjen,**  
*Chief Executive Officer,  
Carina Biotech, Australia*



**Thomas Preiss,**  
*Director, Shine-Dalgarno Centre for  
RNA Innovation, Professor of RNA  
Biology, The Australian National  
University, Australia*



**Joshua Ooi,**  
*Head, Regulatory T-cell Therapies,  
Translational Research Facility,  
Clinical Sciences at Monash Health,  
Monash University, Australia*



**Chunlin Xin,**  
*Vice President of External R&D,  
CanSino Biologics, China*



**David Winkler,**  
*Professor of Biochemistry and Chemistry,  
La Trobe University, Australia*



**Vihandha Wickramasinghe,**  
*Head, RNA Biology and  
Cancer Laboratory,  
Peter MacCallum Cancer Centre,  
Australia*



**Graham Heery,**  
*Associate Director Nonclinical & CMC,  
Starpharma, Australia*



**Ebony Fietz,**  
*Drug Development Manager,  
Currus Biologics, Australia*



**Xenia Sango,**  
*Chief Executive Officer and  
Managing Director,  
Vivazome Therapeutics, Australia*



**Lucas Litewka,**  
*Director of Clinical Trials Centre,  
University of the Sunshine Coast,  
Australia*



**Paul McDonald,**  
*Chief Executive Officer,  
IDT, Australia*



# SPEAKERS 2025

## Speakers



**Michelle McIntosh,**  
*Theme Leader, Drug Delivery,  
Disposition and Dynamics,  
Monash University, Australia*



**Ben Hughes,**  
*Director of Strategic Development,  
Therapeutic Innovation Australia,  
Australia*



**Hemasunder Reddy,**  
*Director - Asia Pacific,  
Pfanstiehl, Singapore*



**John Robson,**  
*Managing Director,  
BioOra, New Zealand*



**Mike Zablocki,**  
*General Manager, Malaghan Institute  
of Medical Research, New Zealand*



**Tam Nguyen,**  
*Deputy Director of Research,  
St. Vincent's Hospital, Australia*



**Diego Correa,**  
*VP & Global Head, Cell and Gene  
Therapy Center of Excellence  
(CAGT-COE), IQVIA, US*



**Phillip Elliott,**  
*Associate Director of Process  
Development, BioCina, Australia*



**Tim Hirst,**  
*Chairman & CEO,  
GPN Vaccines, Australia*



**Oksana Zdanska,**  
*Medical Director,  
ImmVirX, Australia*



**Shigetomo Tsujihata,**  
*General Manager,  
FUJIFILM Toyama Chemical, Japan*



**Edmund Ang, Ph.D.,**  
*Senior Technical Expert, APAC, BioReliance®  
Contract Testing Services, Life Science  
Services, Merck Life Science, Singapore*



**Colin Pouton,**  
*Professor of Pharmaceutical Biology,  
Monash University, Australia*



**Lukasz Kowalczyk,**  
*Senior Scientist,  
AdAlta, Australia*



**Marija Dramicanin,**  
*Head of Protein Production Facility,  
Advanced Technology & Biology  
Division, WEHI Protein Production  
Facility, Australia*



**Bakalar Blaž,**  
*Product Manager,  
Sartorius, Slovenia*

# AGENDA AT A GLANCE

Pre Conference [3 <sup>rd</sup> Feb 2025, Monday]	DAY 1 [4 <sup>th</sup> Feb 2025, Tuesday]	DAY 1 [4 <sup>th</sup> Feb 2025, Tuesday]
<div>Pre Conference Workshop 2:00PM - 6:00PM</div> <div>SARTORIUS</div>	ANZ Biologics Festival 2025	ANZ Next-Gen Cell & Gene Therapeutics Forum
	Current And Future State of the ANZ Biologics Market	Current & Future Prospects for Cell & Gene Therapies in ANZ
	Advances in Vaccine Safety and Efficacy	
	Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking	
	Upstream Processing - Process Optimization & Intensification	Translational Strategy for Pre-Clinical and Clinical Programs
	Lunch Break, Exhibition Viewing & 1-1 Attendee Networking	
	Regulatory Strategies for Advancing Next-Generation Therapies	CGT Manufacturing: Innovations for Safe, Efficient & Scalable Therapies
	Exploring Australian Biopharma: Case Studies	
	Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking	
	Exploring Australian Biopharma: Case Studies	Case Studies: Promising CGT Therapies from ANZ
End of Conference Day 1		

DAY 2 [5 <sup>th</sup> Feb 2025, Tuesday]	DAY 2 [5 <sup>th</sup> Feb 2025, Tuesday]	Post Conference [6 <sup>th</sup> Feb 2025, Thursday]  <
---	---	--

FOR SPEAKING OPPORTUNITIES, KINDLY CONTACT:

**Sarmila Silvaraja,**

Conference Producer

e: sarmila.silvaraja@imapac.com | p: +60126969611

**Vanessa Lim,**

Associate Conference Producer

e: vanessa.lim@imapac.com | p: +60-1133332369



# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

ANZ Biologics Festival 2025 Day 1 [4 <sup>th</sup> Feb 2025, Tuesday]		ANZ Next-Gen Cell & Gene Therapeutics Forum Day 1 [4 <sup>th</sup> Feb 2025, Tuesday]	
8:50	IMAPAC's Opening Remarks	8:50	IMAPAC's Opening Remarks
8:55	Chairman Opening Remarks • <b>Albert Garcia Minambres</b> , Senior Manager, <b>CSL, Australia</b>	8:55	Chairman Opening Remarks • <b>Joshua Ooi</b> , Head, Regulatory T-cell Therapies, Translational Research Facility, Clinical Sciences at Monash Health, <b>Monash University, Australia</b>
Current And Future State of the ANZ Biologics Market		Current & Future Prospects for Cell & Gene Therapies in ANZ	
9:00	<b>Leadership Panel Discussion: International Collaboration Opportunities: Partnering with Emerging Markets and Established Regions</b>  › Strategies for fostering partnerships with Europe, North America, and Asia › Competitive advantages of the ANZ region in the global market › Potential challenges and solutions in international collaborations › Role of government and industry in facilitating global partnerships  <b>Moderator: Tam Nguyen</b> , Deputy Director of Research, <b>St. Vincent's Hospital, Australia</b>  <b>Panellists:</b> • <b>Larisa Chisholm</b> , Chief Operating Officer, <b>Denteric, Australia</b> • <b>Nicholas Huntington</b> , Co-founder & CSO at <b>oNKO-Innate</b> , Director of Research, Cancer Immunology at <b>Monash University, Australia</b> • <b>Jerry Kanellos</b> , Chief Scientific Officer, <b>Immuron, Australia</b>	9:00	<b>Leadership Panel Discussion: Roadmap to Transforming Healthcare: Cell &amp; Gene Therapies in the ANZ Region</b>  › Explore the transformative potential of cell and gene therapies in reshaping healthcare delivery in Australia and New Zealand › Discuss strategic pathways, policy frameworks, and regulatory landscapes crucial for fostering innovation and patient access › Engage with key stakeholders, including industry leaders, policymakers, clinicians, and patient advocates, to outline a collaborative roadmap for accelerating the integration and adoption of these groundbreaking therapies in ANZ  <b>Moderator: Michael Baker</b> , Chief Executive Officer & Managing Director, <b>Arovella Therapeutics, Australia</b>  <b>Panellists:</b> • <b>Deborah Rathjen</b> , Chief Executive Officer, <b>Carina Biotech, Australia</b> • <b>Rebecca McQualter</b> , Chief Operating Officer, <b>Chimeric Therapeutics, Australia</b> • <b>Tim Oldham</b> , Chief Executive Officer & Managing Director, <b>AdAlta, Australia</b>

# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

9:50	<b>Keynote Presentation: Ryoncil: First MSC Therapy To Receive US FDA Approval</b>  <b>Silviu Itescu</b> , Chief Executive Officer, <b>Mesoblast, Australia</b>	9:45	<b>Plug &amp; Play Purification of pDNA Modalities Using Monolith</b>  <b>Speakers:</b> <ul style="list-style-type: none"> <li>• <b>Phillip Elliott</b>, Associate Director of Process Development, <b>BioCina, Australia</b></li> <li>• <b>Bakalar Blaž</b>, Product Manager, <b>Sartorius, Slovenia</b></li> </ul>
		10:00	<b>Keynote Presentation: The Regulation of Cell and Gene Therapies in Australia</b>  <b>Mathew Adams</b> , Senior Evaluator – Biological Science Section, Scientific Evaluation Branch, <b>Therapeutic Goods Administration, Australia</b>
<b>Advances in Vaccine Safety and Efficacy</b>			
10:20	<b>Reducing Inflammatory Responses In mRNA Vaccines: Improving Safety and Efficacy</b> <ul style="list-style-type: none"> <li>› Ultra-short oligonucleotides (oligos) can down regulate inflammatory responses induced by RNAs</li> <li>› Oligos have highly targeted effects on TLR7/8 receptors (and others)</li> <li>› Broad applicability for a) co-packaging oligos with RNA therapeutics &amp; vaccines and b) use as standalone autoimmune drugs</li> </ul> <b>Gisela Mautner</b> , Chief Executive Officer and Managing Director, <b>Noxopharm, Australia</b>	10:25	<b>Market Trends &amp; Investment Landscape for Cell and Gene Therapy in ANZ</b> <ul style="list-style-type: none"> <li>› Current market trends and investment opportunities in cell and gene therapies across Australia and New Zealand</li> <li>› The attractiveness of ANZ as a hub for biotech investments, venture capital interest, and funding mechanism</li> <li>› Emerging trends, economic factors, and regulatory developments shaping the future of cell and gene therapy in the region</li> </ul> <b>Tim Oldham</b> , Chief Executive Officer & Managing Director, <b>AdAlta, Australia</b>



# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

10:50	Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking	10:50	Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Advances in Vaccine Safety and Efficacy		Translational Strategy for Pre-Clinical and Clinical Programs	
11:20	<p><b>The Need for a Serotype-Independent Pneumococcal Vaccine</b></p> <ul style="list-style-type: none"> <li>› based on a photon-inactivated whole-cell vaccine</li> <li>› with a simple, saleable manufacturing process</li> <li>› clinical trials have shown the vaccine is safe, well-tolerated and immunogenic</li> </ul> <p><b>Tim Hirst</b>, Chairman &amp; Chief Executive Officer, <b>GPN Vaccines, Australia</b></p>	11:20	<p><b>Advancing CAR-iNKT Cells into Clinical Trials: A New Frontier in Cancer Immunotherapy</b></p> <p><b>Michael Baker</b>, Chief Executive Officer &amp; Managing Director, <b>Arovella Therapeutics, Australia</b></p>
Upstream Processing: Process Optimization & Intensification			
11:50	<p><b>Polysorbate Degradation Challenges and Risk Mitigation Strategies</b></p> <ul style="list-style-type: none"> <li>› Polysorbate 80 – Role as surfactant, issues with degradation and consequences</li> <li>› Approaches to mitigate transition metal/elemental impurities induced PS80 oxidation and protein fragmentation</li> <li>› Histidine buffer Buffers in commercial antibody formulations – Importance of utilization of highly characterized AAs as Excipients</li> <li>› Degradation of Polysorbate 80 in Histidine buffer – Histidine from Pfanstiehl vs. Competitors</li> </ul> <p><b>Hemasunder Reddy</b>, Director Asia Pacific, <b>Pfstiehl, Singapore</b></p>	11:45	<p><b>Cell and Gene Therapies: Trends, Challenges, and Opportunities in ANZ</b></p> <ul style="list-style-type: none"> <li>› Global Trends in Cell and Gene Therapies: Exploring advancements in oncology and other fields, and their implications for ANZ.</li> <li>› Navigating Challenges and Leveraging Success Factors: Strategies for ANZ to capitalize on emerging opportunities.</li> <li>› Embracing a Long-Term Perspective: Focusing beyond early-phase clinical trials to ensure sustainable growth and innovation.</li> </ul> <p><b>Diego Correa</b>, VP &amp; Global Head, Cell and Gene Therapy Center of Excellence (CAGT-COE), <b>IQVIA, US</b></p>

# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

12:10	<b>Complex Formulations Merging Small Molecule and Biologics</b>  <b>Paul McDonald</b> , Chief Executive Officer, IDT Australia, Australia	12:00	<b>In vivo cancer immunotherapies delivered by CRISPR and RNA-based technology</b>  › Establishment of the Immune Oncology Centre at ONJCRI › Engineering of CAR T cells › Identification of new therapy targets using diverse CRISPR approaches  <b>Marco Herold</b> , Chief Executive Officer, <b>Olivia Newton-John Cancer Research Institute</b> , Head, School of Cancer Medicine, <b>La Trobe University</b> , Honorary Professorial Fellow, <b>University of Melbourne</b> , <b>NHMRC Investigator</b> , Australia
		12:25	<b>Engineered Antigen-Specific TCR-Tregs to Treat Autoimmune Disease</b>  <b>Joshua Ooi</b> , Head, Regulatory T-cell Therapies, Translational Research Facility, Clinical Sciences at Monash Health, <b>Monash University</b> , Australia
12:40	<b>Lunch Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b>	12:50	<b>Lunch Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b>



# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

Regulatory Strategies for Advancing Next-Generation Therapies		CGT Manufacturing: Innovations for Safe, Efficient, and Scalable Therapies	
1:50	<p><b>Panel Discussion: Navigating the Regulatory Landscape for Biologics: Ensuring Compliance and Accelerating Innovation</b></p> <ul style="list-style-type: none"> <li>› Navigating regulatory pathways for advanced therapies</li> <li>› Balancing compliance with technological innovation</li> <li>› Global regulatory alignment to accelerate the development of next-generation therapies</li> </ul> <p><b>Moderator: Ben Hughes</b>, Director of Strategic Development, <b>Therapeutic Innovation Australia, Australia</b></p> <p><b>Panellists:</b></p> <ul style="list-style-type: none"> <li>• <b>Craig Newton</b>, Executive Director &amp; Founder, <b>VivaZome Therapeutics, Australia</b></li> <li>• <b>Silviu Itescu</b>, Chief Executive Officer, <b>Mesoblast, Australia</b></li> <li>• <b>Ilya Vensky</b>, Co-founder and Chief Executive Officer, <b>Helico Bio, New Zealand</b></li> <li>• <b>Xenia Sango</b>, Chief Executive Officer and Managing Director, <b>Vivazome Therapeutics, Australia</b></li> </ul>	1:50	<p><b>Advances in CAR-T Therapies for Solid Tumors</b></p> <p><b>Rebecca McQualter</b>, Chief Executive Officer, <b>Chimeric Therapeutics, Australia</b></p>
		2:15	<p><b>Partnering for Impact – Blending research excellence with commercial expertise to deliver better patient outcomes</b></p> <ul style="list-style-type: none"> <li>› Successful partnerships between research institutes and commercial partners require shared goals and strong governance</li> <li>› Moving from an R&amp;D project and through a phasetrial towards scale up GMP manufacturing requires significant alignment of vision</li> <li>› Managing philanthropic funding with venture capital investment to achieve global impact is rewarding</li> <li>› Conclusion: This partnership leverages the strengths of both organizations to push the boundaries of cancer treatment and to improve patient outcomes</li> </ul> <p><b>Speakers:</b></p> <ul style="list-style-type: none"> <li>• <b>John Robson</b>, Managing Director, <b>BioOra, New Zealand</b></li> <li>• <b>Mike Zablocki</b>, General Manager, <b>Malaghan Institute of Medical Research, New Zealand</b></li> </ul>

# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

Exploring Australian Biopharma: Case Studies			
2:40	<b>Genetic Medicines at CSL and Beyond</b> <b>Ellen Otte, Director, CSL, Australia</b>	2:40	<b>Advances in QC Testing Methods and Regulatory Guidance in Addressing CMC Challenges of CGT Products</b> <ul style="list-style-type: none"> <li>› CGT products and their manufacturing intermediates encompass a wide spectrum of modalities with specific QC requirements</li> <li>› Recent updates in regulatory guidance have highlighted alternative approaches to address certain well known CMC challenges of CGT</li> <li>› Advanced QC methods are available to address CMC challenges of test materials of more complex nature and/or limited amount.</li> </ul> <b>Edmund Ang, Senior Technical Expert Asia Pacific, BioReliance Contract Testing Services, Life Science Services, Merck, Singapore</b>
3:10	<b>Fireside Chat: Assessing and Selecting a Commercial Target in Early-Stage Biotech</b> <b>Moderator: Xenia Sango, Chief Executive Officer and Managing Director, Vivazome Therapeutics, Australia</b> <b>Panellist: Craig Newton, Executive Director &amp; Founder, VivaZome Therapeutics, Australia</b>	2:55	<b>Clinical development of CAR-T cell therapy for Hematologic malignancy</b> <ul style="list-style-type: none"> <li>› Update on phase I trial for NHL</li> <li>› Clinical use for ALL</li> <li>› CAR-T as bridging therapy to BMT</li> </ul> <b>Cheng-Yi Jerry Kuo, Vice General Manager, UWELL Biopharma, Taiwan</b>
		3:20	<b>Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies</b> <b>Ian Nisbet, Chief Operating Officer, Cartherics, Australia</b>

# CONFERENCE DAY 1

4<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

3:40	Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking	3:45	Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exploring Australian Biopharma: Case Studies		Case Studies: Promising CGT Therapies from ANZ	
4:10	<p><b>Cynata Cymerus Technology and Clinical Trial Results: Phase 1 Trial of CYP-006TK in Diabetic Foot Ulcers</b></p> <p><b>Jolanta Airey</b>, Chief Medical Officer, Cynata Therapeutics, Australia</p>	4:15	<p><b>Identification of New Therapeutic Approaches to Overcome Resistance to CAR-T Cell Therapy</b></p> <ul style="list-style-type: none"> <li>› Current CAR-T cell therapy climate</li> <li>› Resistance mechanisms to CAR-T cell therapy</li> <li>› Strategies to improve CAR-T cell therapy responses</li> </ul> <p><b>Jane Oliaro</b>, Chief Scientist, <b>Peter MacCallum Cancer Centre</b>, Australia</p>
4:40	<p><b>Global Market Expansion of an Australian Product Travelan: Strategic Collaborations, Partnerships, Funding and Clinical Trials</b></p> <p><b>Jerry Kanellos</b>, Chief Scientific Officer, Immuron, Australia</p>	4:40	<p><b>Leveraging BEAT Technology to Enhance CAR-T Cell Efficacy</b></p> <ul style="list-style-type: none"> <li>› The BEAT: an innovative approach to achieve CAR T-cell efficacy in solid tumours harnessing the body's own immune system</li> <li>› Insights into the process of developing a therapy combining a biologic and cellular therapy</li> </ul> <p><b>Ebony Fietz</b>, Drug Development Manager, <b>Currus Biologics</b>, Australia</p>
5:10	End of Conference Day 1	5:10	End of Conference Day 1
5:10	Cocktails and Networking	5:10	Cocktails and Networking

# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

ANZ Biologics Festival 2025 DAY 2 [5 <sup>th</sup> Feb 2025, Wednesday]		ANZ Next-Gen Cell & Gene Therapeutics Forum DAY 2 [5 <sup>th</sup> Feb 2025, Wednesday]	
8:50	IMAPAC's Opening Remarks	8:50	IMAPAC's Opening Remarks
8:55	Chairman Opening Remarks <ul style="list-style-type: none"><li>• <b>Marija Dramicanin</b>, Head of Protein Production Facility, Advanced Technology &amp; Biology Division, <b>WEHI Protein Production Facility, Australia</b></li></ul>	8:55	Chairman Opening Remarks <ul style="list-style-type: none"><li>• <b>Jennifer Short</b>, Director, <b>Advanced mRNA Medicines Manufacturing and Workforce Training, Australia</b></li></ul>
	Bioprocessing 4.0: Digitalization, AI and Machine Learning for Manufacturing Efficiencies	Growing RNA Research & Manufacturing Capability in the ANZ Region	
9:00	AI-Driven Plant Expression for Rapid Biologics Production  <b>Ilya Vensky</b> , Co-founder and Chief Executive Officer, <b>Helico Bio, New Zealand</b>	9:00	<b>Panel Discussion: Unlocking the Potential of RNA Therapies: Challenges and Opportunities in the ANZ Region</b> <ul style="list-style-type: none"><li>› Regulatory landscape for RNA therapeutics in Australia and New Zealand</li><li>› Overcoming technical and logistical challenges in RNA manufacturing</li><li>› Investment and funding opportunities to support RNA research and production</li><li>› The role of public-private partnerships in accelerating RNA therapeutic developments</li></ul> <b>Moderator: John Power</b> , Senior Director, <b>BioNTech SE, Australia</b>  <b>Panellists:</b> <ul style="list-style-type: none"><li>• <b>Marco Herold</b>, Chief Executive Officer, <b>Olivia Newton-John Cancer Research Institute</b>, Head, School of Cancer Medicine, <b>La Trobe University</b>, Honorary Professorial Fellow, <b>University of Melbourne</b>, <b>NHMRC Investigator, Australia</b></li><li>• <b>Vihandha Wickramasinghe</b>, Inaugural Moderna Australia Fellow, Head, RNA Biology and Cancer Laboratory, <b>Walter and Eliza Hall Institute, Melbourne, Australia</b></li><li>• <b>Greg Troiano</b>, Head of cGMP Strategic Supply and Operations, Chief Manufacturing Officer, mRNA CoE, <b>Sanofi, US</b></li><li>• <b>Colin Pouton</b>, Professor of Pharmaceutical Biology, <b>Monash University, Australia</b></li></ul>



# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

9:30	<b>Innovations in Protein Production: Enabling Research and Therapeutic Advancements</b> <ul style="list-style-type: none"> <li>› Advancing Protein Production with AI</li> <li>› The Future of Protein Production</li> <li>› Working with Our Facility</li> </ul> <b>Marija Dramicanin</b> , Head of Protein Production Facility, Advanced Technology & Biology Division, <b>WEHI Protein Production Facility, Australia</b>	9:45	<b>Designing LNPs with Proprietary Ionizable Lipids to Expand the Possibilities for mRNA Delivery</b> <ul style="list-style-type: none"> <li>› End-to-end CDMO services for mRNA-LNP</li> <li>› Designing LNPs with proprietary ionizable lipids for mRNA delivery</li> <li>› Particle characterization of LNPs</li> </ul> <b>Shigetomo Tsujihata</b> , General Manager, <b>FUJIFILM Toyama Chemical, Japan</b>
10:00	<b>Use of AI in Therapeutic Discovery – drugs, biologics, and vaccines</b> <ul style="list-style-type: none"> <li>› AI and machine learning are becoming extremely powerful, very broadly applicable platform technologies for science and medicine</li> <li>› Although simpler machine learning methods have been applied usefully for several decades, new deep learning and large language models represent a paradigm shift in research methods.</li> <li>› Examples presented in the paper illustrate the power of these advanced computational methods to accelerate vaccine, biologic, and drug discovery</li> </ul> <b>David Winkler</b> , Professor of Biochemistry and Chemistry, <b>La Trobe University, Australia</b>	10:00	<b>Opportunities and Challenges of mRNA Products</b> <ul style="list-style-type: none"> <li>› How the mRNA field is overcoming many of the early CMC challenges to realize its enormous potential</li> <li>› Some remaining supply chain challenges for mRNA technologies</li> <li>› How Sanofi is leveraging its Australian Translational Science hub to innovate its mRNA platform</li> </ul> <b>Greg Troiano</b> , Head of cGMP Strategic Supply and Operations, Chief Manufacturing Officer, mRNA CoE, <b>Sanofi, US</b>
10:30	<b>Morning Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b>	10:25	<b>Morning Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b>
<b>Translational Strategy for Pre-Clinical and Clinical Programs</b>		<b>Regulatory and Policy Perspectives on RNA and mRNA Therapies</b>	

# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

11:00	<p><b>Bridging the Gap Between Research and Clinical Trials: Translating Biologics Discovery for Successful Clinical Outcomes</b></p> <ul style="list-style-type: none"> <li>› The knowledge for translating basic research to a successful Phase I clinical endpoint is not widely known nor easily obtained.</li> <li>› For over 15 years, the National Biologics Facility (NBF) has been an invaluable resource for researchers, guiding them from lab-scale biopharmaceutical research to scalable, industry-ready processes and Phase I-enabling manufacturing.</li> <li>› This talk will unveil key program milestones and the quality, technical, and process requirements of early-stage development, enriched with case studies and essential lessons learned to manage project risks and drive success in translational research.</li> </ul> <p><b>Ben Hughes</b>, Director of Strategic Development, <b>Therapeutic Innovation Australia, Australia</b></p>	11:00	<p><b>Keynote Presentation: Regulation of mRNA Medicines: Opportunities and Challenges</b></p> <ul style="list-style-type: none"> <li>› Development of mRNA vaccines and medicines</li> <li>› Building on knowledge applied to the pandemic</li> <li>› Regulatory frameworks today and tomorrow</li> </ul> <p><b>Carolyn Tucek-Szabo</b>, Senior Director, Global Regulatory Sciences Lead - Australia/NZ; Policy &amp; Liaison - SE Asia, <b>Moderna, Australia</b></p>
11:30	<p><b>Fireside Chat: Development Planning for Biologics: Navigating the Path from Preclinical to Market</b></p> <ul style="list-style-type: none"> <li>› Key considerations and strategies for scaling biologics from preclinical through to clinical trials</li> <li>› Best practices for aligning development plans with regulatory and commercial milestones</li> </ul> <p><b>Moderator: Ilya Vensky</b>, Co-founder and Chief Executive Officer of <b>Helico Bio, New Zealand</b></p> <p><b>Panellist: Xenia Sango</b>, Chief Executive Officer and Managing Director, <b>Vivazome Therapeutics, Australia</b></p>	11:25	<p><b>Building the mRNA Vaccine Value Chain – A Public Policy Perspective</b></p> <p><b>Rebecca Skinner</b>, Director, Research and Industry Development, mRNA Victoria, <b>Department of Jobs, Skills, Industry and Regions, Australia</b></p>

# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

12:00	<b>Clinical Trial Optimisation - Enhancing Clinical Trial Implementation</b>  <b>Lucas Litewka</b> , Director - Clinical Trials, University of Sunshine Coast, Australia	11:50	<b>Pathways for Translation of mRNA Technology from Bench to Clinic: BioNTech Australia</b>  <b>John Power</b> , Senior Director, BioNTech SE, Australia
12:30	<b>Lunch Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b>	12:15	<b>Lunch Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b>
<b>Innovations in Drug Delivery and Translational Strategies for Therapeutics</b>		<b>Accelerating Vaccine Manufacture with mRNA Technology</b>	
1:30	<b>oNKo-044: A Next Generation Targeted Cytokine Therapy for the Treatment of Solid Tumours</b>  <ul style="list-style-type: none"> <li>› The clinical utility of traditional cytokine-based drugs has been severely limited by their narrow therapeutic index</li> <li>› oNKo-044 is a class-leading interleukin-12 (IL-12) biologic that has been engineered to minimise toxicity and extend half-life, all whilst retaining potent activity within the tumour microenvironment</li> <li>› Mechanistically, oNKo-044 focuses IL-12 activity on the most relevant tumour-infiltrating immune cell types via a cis-mediated surface capture effect</li> </ul> <b>Richard Berry</b> , Vice President, Biologics & Drug Discovery, oNKo-innate, Australia	1:45	<b>Building mRNA Capabilities: CanSino's Journey and China's mRNA Vaccine Landscape</b>  <b>Chunlin Xin</b> , Vice President of External R&D, CanSino Biologics, China

# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

2:00	<p><b>Enhancing Delivery of Anticancer Therapies with Dendrimer Nanoparticles</b></p> <ul style="list-style-type: none"> <li>› Starpharma's polylysine DEP<sup>®</sup> dendrimers are flexible and versatile in terms of size, dendrimer/payload ratio and solubility</li> <li>› The DEP<sup>®</sup> dendrimer structures can be finely tuned to elicit favourable biodistribution and excretion profiles to complement the needs of specific therapeutic uses; e.g. avoiding renal elimination for radiotherapeutics or increasing drug exposure and bioavailability</li> <li>› The DEP platform is target and targeting type agnostic. Can be combined mAb's, antibody mimetics (VHH, affibodies etc), peptides or small molecules to elicit tumour accumulation for any molecular target (e.g. Her2, PSMA etc)</li> </ul> <p><b>Graham Heery</b>, Associate Director Nonclinical &amp; CMC, <b>Starpharma, Australia</b></p>	2:10	<p><b>Harnessing mRNA Technology to Combat Tuberculosis</b></p> <ul style="list-style-type: none"> <li>› Challenges of TB vaccine development</li> <li>› Pre-clinical assessment of novel mRNA vaccine for TB</li> <li>› Comparison of mRNA vaccines vs. conventional antigen-adjuvant vaccines</li> </ul> <p><b>Jamie Triccas</b>, Deputy Director, Sydney Infectious Diseases Institute, Infection, Immunity and Inflammation Theme, School of Medical Sciences, Faculty of Medicine and Health, <b>The University of Sydney, Australia</b></p>
			<p><b>Case Studies: Breakthrough RNA Therapies</b></p> <p><b>IVX037: Promising Clinical Stage RNA Oncolytic Immunotherapy for the Most Globally Prevalent Solid Tumours</b></p> <ul style="list-style-type: none"> <li>› Immune checkpoint inhibitors are effective in only minority of patients with advanced solid cancers.</li> <li>› ImmVirX's oncolytic immunotherapies are intended to increase the effectiveness of current therapies, primarily immune checkpoint inhibitors, in fighting cancers of high unmet need including colorectal, gastric, hepatocellular and ovarian cancer.</li> <li>› IVX037 is a self-amplifying non-enveloped, single-positive-stranded RNA virus that has been bioselected to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses.</li> </ul> <p><b>Oksana Zdanska</b>, Medical Director, <b>ImmVirX, Australia</b></p>



# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

2:30	<p><b>Translating Nasal and Pulmonary Drug Delivery Innovations from Lab to Clinic: Challenges and Opportunities</b></p> <p><b>Michelle McIntosh</b>, Director Medicines Manufacturing Innovation Centre, <b>Monash University, Australia</b></p>		
3:00	<p><b>Fireside Chat: Navigating the quality, timelines and budget for continuous improvement and process development in protein production</b></p> <p><b>Moderator:</b> Michelle McIntosh, Director Medicines Manufacturing Innovation Centre, <b>Monash University, Australia</b></p> <p><b>Panellist:</b> Lukasz Kowalczyk, Senior Scientist, <b>AdAlta, Australia</b></p>	3:00	<p><b>Developing First-in-class RNA Processing Inhibitors: From Fundamental Biology to Commercialisation</b></p> <p><b>Vihandha Wickramasinghe</b>, Inaugural Moderna Australia Fellow, Head, RNA Biology and Cancer Laboratory, <b>Walter and Eliza Hall Institute, Melbourne, Australia</b></p>
3:30	<p><b>Afternoon Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>	3:25	<p><b>Afternoon Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>

# CONFERENCE DAY 2

5<sup>th</sup> Feb 2025 | The Crown Promenade Melbourne, Australia

End of Conference Day 2

## Case Studies: Breakthrough RNA Therapies from ANZ

### The ANU Shine-Dalgarno Centre for RNA Innovation

3:55

- › Biomimetic features of RNA therapeutics
- › Design, testing and optimisation of RNA modalities
- › Coordination within the ANZ RNA R&D landscape

**Thomas Preiss**, Director of Shine-Dalgarno Centre for RNA Innovation, Professor of RNA Biology, **The Australian National University, Australia**

### Building a skilled workforce to support the growing RNA ecosystem

4:20

- › RNA medicines discovery, development and manufacturing in Australia: current state of play
- › Future workforce capabilities: how to identify and add value to the talent pipeline
- › Flexible educational models: curricular design that supports meaningful knowledge and skill development for learners at every stage in their career

**Jennifer Short**, Director, **Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training, Australia**

4:45

End of Conference Day 2

# 5 MOST POPULAR SESSIONS 2025



**The Regulation of Cell  
and Gene Therapies  
in Australia**



**Opportunities and  
Challenges of  
mRNA Products**



**Ryoncil:  
First MSC Therapy  
to Receive US FDA  
Approval**



**Complex Formulations  
Merging Small Molecule  
and Biologics**



**Panel Discussion:  
Unlocking the Potential of RNA Therapies:  
Challenges and Opportunities in the ANZ Region**


# ATTENDEES BREAKDOWN

**81%** | ATTENDEES FROM AUSTRALIA

BioPharmas, BIG Pharma, Academic & Research Institutes,  
CMO/CDMO, CRO, Solution Providers


## By Region

- China
- India
- Japan
- South East Asia
- South Korea
- United States and Europe



## By Industry

- Analytical
- Business Development/Marketing Communications
- C-Level
- Clinical Development/Clinical Trials
- Manufacturing/MSAT
- Others
- Quality & Compliance
- Research & Development
- Supply Chain & Logistics






# ATTENDEES BREAKDOWN

**81%** | ATTENDEES FROM AUSTRALIA

BioPharmas, BIG Pharma, Academic & Research Institutes, CMO/CDMO, CRO, Solution Providers

## By Department



- Academic & Research Institute
- Big Pharma
- CMO/CDMO/CRO
- Government & Regulator
- Others
- Technology/Solution Providers
- Biopharma
- Hospital/Medical Centre

# ATTENDEES LIST

COMPANY	JOB TITLE	COUNTRY
360biolabs	Scientist	Australia
ACROBiosystems	Head of TSS, APAC	China
ACROBiosystems	MKT APAC Manager	China
ACROBiosystems	Vice President of Sales	China
AdAlta	Senior Scientist	Australia
AdAlta Limited	Research Assistant	Australia
AdAlta Limited	Senior Scientist II	Australia
AdAlta Limited	Senior Scientist II	Australia
AdAlta Limited	R&D Scientist	Australia
AdAlta Limited	Chief Executive Officer & Managing Director	Australia
Alfred Health	CAR-T Program Manager	Australia
Almac Group	Business Development Manager	Australia
Arovella Therapeutics	Associate Director Research & Development	Australia
Arovella Therapeutics	Chief Executive Officer & Managing Director	Australia
Arovella Therapeutics	COO	Australia
Australian Red Cross Lifeblood	Principal Advisor – Blood Transfusion Research	Australia
Avantor	Sales Manager - Biopharma Australia & New Zealand	Australia
Axelia Oncology	Director of Clinical Operations	Australia
BioCina	Associate Director of Process Development	Australia
Biocina	Business Development	Australia
Biocytogen	BD	China
Biocytogen	BD	China
BioNTech	Senior Director	Australia
BioOra	Managing Director	New Zealand
BioOra Limited	GMP Production Technician	New Zealand

BioOra Limited	Board Director, Chair of Medical Advisory Board	USA
Biosceptre	Clinical Operations Director	Australia
Biosceptre	Chief Operations Officer	Australia
Biosceptre	Director of Research and Development	Australia
Biosceptre	Chief Scientific Officer	Australia
Biosceptre	Chief Executive Officer (CEO)	Australia
Biosceptre	Biologics Production Manager	Australia
BioTools	Sales Manager (VIC/NSW/TAS/SA)	Australia
BioTools	National Sales Manager - Automation & Integration	Australia
Bovogen	General Manager	Australia
Burnet Institute	Quality Manager	Australia
Burnet Institute	Quality Assurance Specialist	Australia
CanSino Biologics	Vice President of External R&D	China
CanSino Biologics	Manager of BD	China
CanSino Biologics	Senior Director of BD	China
Carina Biotech	Chief Executive Officer	Australia
Cartherics	Chief Operating Officer	Australia
Celleo	Head of Biology	Australia
Chimeric Therapeutics	CFO	Australia
Chimeric Therapeutics	Chief Executive Officer	Australia
Copure Pty Limited	Technical & Sales Director	Australia
CPC	Application Engineer	Singapore
Cryosite	BD Executive	Australia
CSL	Senior Manager of Bioanalytical Sciences	Australia
CSL	Project Manager	Australia
CSL	Clinical Scientist	Australia
CSL	Associate Director of R&D	Australia

CSL	Senior Manager, Global Regulatory Project Management	Australia
CSL Behring	Biotech Manufacturing Associate	Australia
CSL Behring	BMF Compliance Coordinator	Australia
CSL Behring	Senior Manager Downstream	Australia
CSL Behring	BMF Inventory Coordinator	Australia
CSL Behring	Biotech Manufacturing Associate	Australia
CSL Behring	Director Biological Manufacturing Facility	Australia
CSL Seqirus	Senior Global Regulatory Lead	Australia
Currus Biologics	Drug Development Manager	Australia
Currus Biologics	Chief Executive Officer	Australia
Cynata Therapeutics	Senior Clinical Operations Manager	Australia
Cynata Therapeutics	Chief Medical Officer	Australia
Cynata Therapeutics	Director, Regulatory and Scientific Affairs	Australia
Cytiva	Account Manager	Australia
Cytiva	Business Development Manager	Australia
Cytiva	Account Manager	Australia
Cytiva	Product Sales Manager APAC	Australia
Daiichi Sankyo	Senior Director Head GMP Audits	USA
Decode Science	BDM	Australia
Decode Science	Product Manager – Research Genomics	Australia
Denteric Pty Ltd	Chief Operating Officer	Australia
Duopharma (M) SDN BHD	Business Development Executive	Malaysia
Duopharma (M) SDN BHD	Chief Innovation Officer	Malaysia
Endpoints Capital	Chief Executive Officer	Australia
Endpoints Capital	Chief Commercial Officer	Australia



exteRNA	Director of Biology	Australia
Fenix Innovation Group	Scientific Projects Manager	Australia
Fenix Innovation Group	Business Development Manager	Australia
Formulytica	Innovation & Biologics Director	Australia
FUJIFILM Diosynth Biotechnologies Japan	Director, Marketing Operations	Japan
Fujifilm Diosynth Biotechnologies Japan	Project Manager	Japan
FUJIFILM Toyama Chemical	General Manager	Japan
GPN Vaccines	Chief Operating Officer	Australia
GPN Vaccines	Chief Medical Officer	Australia
GPN Vaccines	Chairman & CEO	Australia
Haemalogix	Chief Executive Officer	Australia
Helico Bio	Co-founder and CEO	New Zealand
Hudson Institute of Medical Research ( Cell Therapies)	Production Supervisor	Australia
IDT	Chief Executive Officer	Australia
IDT Australia	Manager	Australia
Immuron	Chief Scientific Officer	Australia
Immuron Limited	Research & Development Manager	Australia
Immuron Limited	Quality Assurance Manager	Australia
Immuron Limited	Pharmacovigilance Associate	Australia
ImmVirX	Director Quality & Regulatory Affairs	Australia
ImmVirX	CEO and Co-Founder	Australia
ImmVirX	Medical Director	Australia
ImmVirX	Project Manager	Australia
INOVIQ Limited	Chief Scientific Officer	Australia
INOVIQ Limited	Quality & Regulatory Manager	Australia
INOVIQ Limited	Chief Executive Officer	Australia
INOVIQ Limited	Research Director	Australia

IQVIA	VP & Global Head, Cell and Gene Therapy Center of Excellence (CAGT-COE)	Australia
IQVIA Biotech	Sr Director, Business Development	Australia
IQVIA Biotech	Head of APAC Strategy, Early Phase Oncology and Innovative Therapies	Australia
IQVIA Biotech	Business Development Manager	Australia
IQVIA Biotech	Therapeutic Strategy	Australia
IQVIA Biotech	Business Development Manager	Australia
JS Biosciences	Chief Technology Officer	China
La Trobe University	Professor of Biochemistry and Chemistry	Australia
LabConnect	General Manager APAC	Australia
Lonza	Director, Commercial, Personalized Medicine	Australia
Malaghan Institute of Medical Research	General Manager	New Zealand
Merck	Head of Sales for Pharma & Biotech - SLS	Australia
Merck	Head of Sales - Process Solutions, ANZ	Australia
Merck	Head of SLS ANZ Commercial Marketing	Australia
Merck	Major Account Manager – Pharma/Biotech	Australia
Merck	Senior Technical Expert Asia Pacific, BioReliance Contract Testing Services, Life Science Services	Singapore
Merck	PMO , APAC, BioReliance Contract Testing Services	Singapore
Merck	Business Development Manager, ANZ & India, BioReliance Contract Testing Services,	Singapore
Merck	Demand Gen Marketing Manager APAC, BioReliance Contract Testing Services	Singapore

Merck Life Science	Regional Strategy Executive APeC, Process Solutions,	Australia
Mesoblast	Chief Executive Officer	Australia
MessengerBio	Co-Founder	Australia
MetaGene	Southern Region Sales Manager	Australia
Moderna	Senior Director: Global Regulatory Sciences Lead - Australia/NZ; Policy & Liaison - SE Asia	Australia
Moderna	Senior Manager, Global Regulatory Sciences	Australia
Moderna	Senior Manager, Regulatory Sciences ANZ	Australia
Moderna Australia	MS&T Drug Substance LEad	Australia
Moderna Australia	Production Team Lead	Australia
Moderna Australia	Site Quality Lead	Australia
Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training	Director	Australia
Monash University	Professor of Pharmaceutical Biology	Australia
Monash University	<u>Head of Clinical Operations</u>	Australia
Monash University	Theme Leader, Drug Delivery, Disposition and Dynamics	Australia
Morimatsu Pharmadule (Singapore) Pte. Ltd	Sales Manager	Singapore
Morimatsu Pharmadule (Singapore) Pte. Ltd	Sales Manager	Singapore
mRNA CoE, Sanofi	Head of cGMP Strategic Supply and Operations, Chief Manufacturing Officer	United States
mRNA Victoria	Research and Development Stakeholder Coordinator	Australia
mRNA Victoria	Senior Advisor	Australia
mRNA Victoria	Lead Investment Manager - Life Sciences and Medical Technologies	Australia
mRNA Victoria	Investment and Partnerships Manager	Australia

mRNA Victoria	Senior Scientific and Policy Advisor,	Australia
mRNA Victoria	Senior Investment Manager	Australia
mRNA Victoria	Research and Industry Development Officer	Australia
mRNA Victoria, Government of Victoria	Director, Research and Industry Development	Australia
NeuClone	CSO	Australia
Novachem	Medical Science Liaison	Australia
Novachem	Proficiency Testing Coordinator	Australia
Novonordisk Phamatech	Bioprocessing Sales Manager, APAC	South Korea
Noxopharm	Chief Executive Officer and Managing Director	Australia
NSW Health	Process Development Scientist	Australia
Nucleus Network	Senior Director of Business Development	Australia
Olivia Newton John Cancer Research Institute	Project Manager	Australia
Olivia Newton-John Cancer Research Institute, La Trobe University, University of Melbourne	CEO, Olivia Newton-John Cancer Research Institute, Head, School of Cancer Medicine, La Trobe University, Honorary Professorial Fellow, University of Melbourne NHMRC Investigator	Australia
oNko-innate	Chief Technology Officer	Australia
oNko-innate	Vice President, Biologics & Drug Discovery	Australia
oNko-Innate & Monash University	Co-founder & CSO at oNko-Innate, Director of Research, Cancer Immunology at Monash University	Australia
Peter MacCallum Cancer Centre	Scientist	Australia
Peter MacCallum Cancer Centre	Chief Scientist	Australia
Peter MacCallum Cancer Centre	Development Scientist	Australia
Peter MacCallum Cancer Centre	Scientist	Australia
Peter MacCallum Cancer Centre	Scientist	Australia

Peter MacCallum Cancer Centre	Project Manager	Australia
Peter MacCallum Cancer Centre	Head, RNA Biology and Cancer Laboratory	Australia
Pfanstiehl	Director-Asia Pacific	Singapore
Pfanstiehl, Inc.	Director	Japan
Prescient therapeutics	Chief Executive Officer	Australia
ProBio	Sr. Commercial BD Manager	Australia
ProBio	Head of the APAC Regional Marketing Team	China
Promega Corporation	Field Applications Specialist	Australia
PSC Biotech Australia	Managing Director	Australia
QuickSTAT A Kuehne+Nagel Compamy	Director, Commercial Operatinos	Australia
QuickSTAT A Kuehne+Nagel Compay	Customer Service Manager	Australia
RNate/ Hudson Insitute of Medical Research	RNate Platform Manager	Australia
RNate/ Hudson Insitute of Medical Research	Quality Specialist	Australia
Sartorius	Sales Development Specialist CMTS	Singapore
Sartorius	Manager of Product Excellence ST ASIA	Singapore
Sartorius	Head of Sales Region ANZ	Singapore
Sartorius	Product Specialist	Singapore
Sartorius	Regional Events Coordinator	Singapore
Sartorius	Regional MarCom Business Partner APAC	Singapore
Sartorius	Manager of Field Application Specialists Advanced Therapy Solutions APAC	Singapore
Sartorius	Head of Sales ATS JAPAC	Singapore
Sartorius	Field Account Manager	Singapore
Sartorius	Product Manager	Slovenia
Sartorius Australia Pty Ltd	Digital Marketing Specialist, APAC	Australia



Sartorius Australia Pty Ltd	Sales Representative - Lab Products and Services	Australia
Sartorius Australia Pty. Ltd.	Technical Sales Specialist (BioAnalytics)	Australia
Sartorius Australia Pty. Ltd.	Field Application Scientist (ANZ), BioAnalytics	Australia
SGS Vitrology	Business Development Manager	United Kingdom
Solve Scientific	Sales Manager	Australia
Solve Scientific	Managing Director	Australia
Southern RNA	Senior QC Scientist	Australia
Southern RNA	Senior Scientist	Australia
St. Vincent's Hospital, Australia	Deputy Director of Research	Australia
Starpharma	Associate Director Nonclinical & CMC	Australia
Syneos Health	General Manager/Managing Director	Australia
Syneos Health	Exec Director of Business Development	Australia
Tech for Life Science	Principal	Australia
Technovalia	Chief Executive Officer	Australia
The Australian National University	Director, Shine-Dalgarno Centre for RNA Innovation, Professor of RNA Biology	Australia
The Ritch Centre/Hudson Institute	Research Scientist	Australia
The Ritch Centre/Hudson Institute	Senior Research Fellow	Australia
The Ritch Centre/Hudson Institute	Research Fellow	Australia
The Ritch Centre/Hudson Institute	Research Scientist	Australia
The Ritch Centre/Hudson Institute	Research Assistant	Australia
The Ritchie Centre, Hudson Institute of Medical Research	Research Scientist	Australia
The University of Melbourne	Research Assistant	Australia

The University of Sydney	Deputy Director, Sydney Infectious Diseases Institute, Infection, Immunity and Inflammation Theme, School of Medical Sciences, Faculty of Medicine and Health	Australia
Therapeutic Goods Administration	Senior Evaluator – Biological Science Section, Scientific Evaluation Branch	Australia
Therapeutic Innovation Australia	Director of Strategic Development	Australia
Thousand Oaks Biologics	Chief Executive Officer	China
Translational Research Facility, Clinical Sciences at Monash Health, Monash University	Head, Regulatory T-cell Therapies	Australia
Treg Therapies Research Group, Monash University	Chief Technology Officer	Australia
Treg Therapies Research Group, Monash University	Chief Operating Officer	Australia
Treg Therapies Research Group, Monash University	Gene Delivery Lead	Australia
Treg Therapies Research Group, Monash University	Chief Executive Officer	Australia
Treg Therapies Research Group, Monash University	Chief Scientific Officer	Australia
University of Queensland (BASE Facility)	Facility Lead	Australia
University of Queensland (BASE Facility)	Postdoc	Australia
University of Queensland (BASE Facility)	Associate Professor	Australia
University of Queensland (BASE Facility)	Professor	Australia
University of Sydney	Research Engagement Manager, Health and Medical	Australia
University of Sydney	Senior Lecturer	Australia
University of Sydney	Research Engagement Manager, Sydney Biomedical Accelerator	Australia
University of Sydney	Associate Director, Business and Research Development	Australia
University of Technology Sydney	BIF Academic Director	Australia
University of Technology Sydney	Project Manager	Australia
University of Technology Sydney	Associate Professor	Australia

University of the Sunshine Coast	Director - Clinical Trials Centre	Australia
UNSW Recombinant Products Facility	Director	Australia
UNSW Recombinant Products Facility	Manager	Australia
UNSW Recombinant Products Facility	Senior Technical Officer	Australia
UWELL Biopharma	Vice General Manager	Taiwan
VFV	Director	Australia
VFV	Sales	Australia
VivaZyme Therapeutics	Executive Director & Founder	Australia
VivaZyme Therapeutics	Chief Executive Officer and Managing Director	Australia
Wacker Biotech	Head ASIA Biopharma	Singapore
WEHI Protein Production Facility	Head of Protein Production Facility at WEHI	Australia

## Agenda

2:00 - 2:30 Registrations | Coffee and Tea

2:30 - 2:40 **Welcome & Introduction**  
*Andreas Kocourek, Head of Sales Region ANZ, Sartorius*2:40 - 3:00 **Setting the Standard in Cell and Gene Therapy, Together**  
This presentation will offer a high-level overview of the current trends for Cell & Gene Therapies, focusing on key industry challenges and customer needs. We will highlight how, as a leading solution provider, we are setting the standard in this evolving field, working together to drive innovation and ensure the successful delivery of transformative therapies.  
*Cheng Qingling, Platform Development Specialist BPS Sales APAC, Sartorius*3:00 - 3:30 **Get a Headstart: Advancing Scalable Cell and Gene Therapies with Quality-Driven Media and Reagents**  
*Mayank Gupta, Product Specialist CMTS CCM, Product Excellence CMTS APAC, Sartorius*3:30 - 3:45 **Linkit® AX – Your Smart Simultaneous Aliquoting Solutions**  
The Linkit® AX solution was expertly designed to overcome the challenges of manual filling and aliquoting, without requiring investment in complex equipment. This advanced aseptic filling system efficiently channels process fluids into 10 Flexsafe® bags, enabling rapid and simultaneous filling. Its plug-and-play design, enhanced by a patented, ready-to-use bag distribution manifold, significantly reduces operator effort and error, ensuring precise fluid distribution into each of the 10 bags with an impressive accuracy of  $\pm 5.1\%$  (applicable for 250mL, 500mL, and 1000mL bags). This makes it an ideal solution for aliquoting small fluid quantities in applications such as small-batch media preparation for cell and gene therapy, as well as other process fluid aliquoting tasks.  
*Clinton Simpson, Product Specialist, Product Excellence FMT APAC, Sartorius*3:45 - 4:00 **Aseptic Cell Harvest & Concentration in Cell Therapy Manufacturing**  
An automated, single-use solution designed to minimize contamination risks by reducing the need for manual handling. Ksep offers scalable counterflow continuous processing for aseptic cell concentration, wash, and harvest in cell therapy manufacturing, supporting high recoveries. By harmonizing a balance between centrifugal and fluid flow forces, it imparts very low shear on cells, ensuring high viability and yield. The automated cell wash feature enhances harvest quality in cell processing applications. The Ksep® system is adaptable from process development (0.1 L) to commercial manufacturing (200 L), providing seamless scalability.  
*Amit Khanna, Manager of Product Excellence ST APAC, Sartorius*

4:00 - 4:10 Break

4:10 - 4:40 **Innovation at its Best: Optimizing Upstream and Downstream Lentivirus Manufacturing Processes for CAR-T Cell Generation**  
While several CAR-T cell therapies are already approved, patient access remains a fundamental challenge. How can manufacturing innovation enable better upstream yields and downstream recovery to reduce cost per dose? In this session we explore innovation at its best to improve plasmid engineering, transient lentivirus production as well as lentiviral purification performance with newly developed chemical modifications for functional CAR-T cell generation.  
*Blaz Bakalar, Product Manager, Sartorius*4:40 - 4:55 **Rapid & Automated Direct Quantification of Total Virus Particles**  
A robust analytical tool delivering virus counts in near real-time. This system is adaptable across various virus growth and purification processes, offering versatility across numerous applications. Pinpoint optimal harvesting periods, validate processing stages, and establish final formulations efficiently and confidently. Viruses are labeled using specific reagents, employing either a direct dye method or high-affinity monoclonal antibodies. Subsequently, samples undergo precise and intense laser illumination. This method facilitates swift, direct, and precise quantification of total virus particles within a sample.  
*Amit Khanna, Manager of Product Excellence ST APAC, Sartorius*4:55 - 5:10 **CAR-T Characterization: Leveraging Live-Cell Analysis and HTS Cytometry**  
"The development of gene modified cell therapies, in particular chimeric antigen receptor (CAR) T-cell therapy, has revolutionized cancer treatment by enabling personalized intelligent medicine, with the potential to cure disease. Owing to the success of CAR T-cell therapy, research in this field has boomed. Still, there are many limitations such as toxicity, limited efficacy against solid tumors, antigen escape, poor trafficking, and tumor infiltration that require to be addressed.  
In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells are necessary. In this talk, we will consider how by leveraging Incucyte®'s live-cell analysis and iQue®'s high-throughput screener by cytometry platforms, researchers can be better equipped at assessing the criteria for developing and advancing future gene modified cell therapies."  
*Nabiha Elias, Ph.D., BioA Field Application Specialist, APAC, Sartorius*5:10 - 5:15 **Q&A and Closing Notes**  
*Andreas Kocourek, Head of Sales Region ANZ, Sartorius*

5:15 onwards Networking

## Speakers

**Andreas Kocourek**  
Head of Sales Region ANZ,  
Sartorius**Cheng Qingling**  
Platform Development  
Specialist BPS Sales APAC,  
Sartorius**Mayank Gupta**  
Product Specialist CMTS  
CCM, Product Excellence  
CMTS APAC,  
Sartorius**Clinton Simpson**  
Product Specialist, Product  
Excellence FMT APAC,  
Sartorius**Amit Khanna**  
Manager of Product  
Excellence ST APAC,  
Sartorius**Blaz Bakalar**  
Product Manager,  
Sartorius**Nabiha Elias, Ph.D.**  
BioA Field Application  
Specialist, APAC,  
Sartorius



# SARTORIUS

## A man in a dark jacket and glasses is standing at a podium, presenting at a Sartorius booth. The booth features a large banner with the Sartorius logo and the text "Setting the Standard in Cell &amp; Gene Therapy Together." and "Simple Progress". To the left, a screen displays "Standard in Cell Therapy, Together" and the Sartorius logo. The background also includes a grid of icons representing various scientific fields like biology, chemistry, and physics.





# SITE TOUR TO IDT AUSTRALIA



IDT Australia is a leading cGMP pharmaceutical manufacturer with over 50 years of expertise, known for bringing 30 novel chemical entities to market. As a go-to partner in pharmaceutical production, IDT excels in advanced technologies like mRNA-based therapeutics, Antibody Drug Conjugates (ADCs), and psychedelic treatments for mental health.

## Key Highlights:

- **GMP-licensed facilities** certified by FDA, PMDA, EU, and TGA for APIs and finished dosage forms.
- **Advanced manufacturing** includes 4,000L reactor capacity, high containment for cytotoxic substances, and mRNA vaccine production expertise.
- **Specialty oral dosage forms** with large-scale production capabilities.
- **Sterile Fill & Finish** services for complex formulations like lipids, emulsions, lyophilization, and nanoparticle encapsulation.
- **Analytical and microbiology labs** supporting global regulatory compliance.



Participants will tour IDT's state-of-the-art facilities, including high containment ADC areas, sterile suites, and pilot scale capabilities, showcasing their leadership in biologics, mRNA vaccines, and advanced therapies.

Date: Thursday, February 6th, 2025

Time: 9:00a.m. – 12:00p.m.

Venue: IDT Australia, 45 Wadhurst Drive, Boronia, Victoria 3155, Australia

Time	Details
08:00 a.m.	Depart from The Crown Promenade Melbourne, Australia
09:00 a.m.	Arrive at IDT Australia
9:45 a.m.	Welcome speech from IDT Australia's Representative
10:15 a.m.	Touring session
11:00 a.m.	Break & networking session
11:30 a.m.	Group photo
11:45 a.m.	Depart from IDT Australia to Crown Promenade Melbourne



# SITE TOUR GALLERY





# SAVE THE DATES

## 4<sup>TH</sup> ANZ **BIOLOGICS** FESTIVAL 2026

### 4<sup>th</sup> & 5<sup>th</sup> February 2026

Melbourne, Australia



#### SPEAKING OPPORTUNITIES

**Sarmila Silvaraja**

Conference Producer

e: [sarmila.silvaraja@imapac.com](mailto:sarmila.silvaraja@imapac.com)  
p: +60126969611

**Vanessa Lim**

Associate Conference Producer

e: [vanessa.lim@imapac.com](mailto:vanessa.lim@imapac.com)  
p: +60-1133332369

#### SPONSORSHIP & EXHIBITION

**Priyanka Lao**

Project Manager

e: [priyanka.lao@imapac.com](mailto:priyanka.lao@imapac.com)  
p: +65 81436248

#### REGISTRATION & MEDIA

**Pooja Zaveri**

Marketing Executive

e: [pooja.zaveri@imapac.com](mailto:pooja.zaveri@imapac.com)

# UPCOMING EVENTS

## 2025-2026

### 2025

#### FEBRUARY 2025

**3rd ANZ Biologics Festival 2025**  
(5 - 6 February 2025)

 Australia

**Cell & Gene Therapy Manufacturing Summit**  
(12 - 13 February 2025)

 Switzerland

**Biologics Manufacturing Germany**  
(18 - 19 February 2025)

 Germany

**Biomanufacturing Ireland**  
(25 - 26 February 2025)

 Ireland

#### MARCH 2025

**15th Edition Vaccines World Summit 2025**  
**9th Edition Biologics Festival India**  
(4 - 5 March 2025)

 India

**Biologics World Nordics**  
(5 - 6 March 2025)

 Sweden

**The 12th Annual Biologics Manufacturing Asia**  
**9th Edition Biologistics World Asia 2025**  
**3rd Clinical Trials Festival Asia 2025**  
**2nd Annual Biologics Digitalization & AI World 2025**  
**ADC Asia Congress 2025**  
(12 - 13 March 2025)

 Singapore

**12th Edition Biologics World Taiwan 2025**  
**4th Edition Stem Cells & Regenerative Medicine**  
**Asia 2025**  
(26 - 27 March 2025)

 Taiwan

#### MAY 2025

**Antibody & TIDES Summit 2025**  
(6 - 7 May 2025)

- Antibody Engineering Europe 2025
- TIDES of Innovation: The Pep & Oligo Summit 2025

 Netherlands



# UPCOMING EVENTS

## 2025-2026

### 2025

**JUNE**  
2025

**Contract Manufacturing Europe**  
(10 - 11 June 2025)

 Scotland

**Biologics World Korea 2025**  
(24 - 25 June 2025)

- Cell & Gene Therapy World East Asia 2025
- Biologics Manufacturing Korea 2025
- ADC & Bioconjugate World East Asia

 Korea

**SEPTEMBER**  
2025

**Cell & Gene World 2025**  
(9 - 10 September 2025)

- Viral Vector Manufacturing Forum 2025
- CAR-T Discovery Forum 2025

 Scotland

**Cell & Gene Therapy World Asia 2025**  
(10 - 11 September 2025)

 Singapore

**Biologics Contract Manufacturing Asia 2025**  
(10 - 11 September 2025)

 Singapore

**Vaccine World Asia Congress - SEA 2025**  
(24 - 25 September 2025)

 Thailand

**NOVEMBER**  
2025

**Antibody & TIDES Asia Summit 2025**  
(12 - 13 November 2025)

- Antibody Engineering Asia 2025
- TIDES of Innovation: The Pep & Oligo Summit Asia 2025

 Japan

**DECEMBER**  
2025

**BioFormulate Live 2025**  
(2 - 3 December 2025)

- RNA Therapeutics & Development 2025
- Vaccine Innovations 2025
- Biologics Formulation & Delivery 2025

 Spain



# UPCOMING EVENTS

## 2025-2026

2026

FEBRUARY  
2026

### Biologics World DACH 2026

(11 - 12 February 2026)

- Cell & Gene Therapy Manufacturing DACH 2026
- BioManufacturing DACH 2026
- BioLogistics DACH 2026

 Germany

### Biologics World Ireland 2026

(22 - 23 February 2026)

- CGT Ireland 2026
- BioManufacturing Ireland 2026
- BioLogistics Ireland 2026

 Ireland

### ANZ Biologics Festival 2026

(4 - 5 February 2026)

 Australia

MARCH  
2026

### Vaccines World Summit 2026

(4 - 5 March 2026)

 India

### Great India Biologics Festival 2026

(4 - 5 March 2026)

 India

### Contract Manufacturing USA 2026

(10 - 11 March 2026)

 United States

### Biologics World Asia 2026

(11 - 12 March 2026)

- Clinical Trials Festival Asia 2026
- BioLogistics World Asia 2026
- Biologics Manufacturing Asia 2026
- Biologics Digitalisation & AI 2026
- ADC Asia 2026

 Singapore

### Biologics World Nordics 2026

(24 - 25 March 2026)

- CGT Nordics 2026
- Biologics Nordics 2026

 Scotland

### Biologics World Taiwan 2026

(25 - 26 March 2026)

 Taiwan

# UPCOMING EVENTS

## 2025-2026

### 2026

**MAY**  
2026

**TIDES of Innovation: The Pep & Oligo Summit 2026**  
(7 - 8 May 2026)

 Netherlands

**Antibody Engineering Europe 2026**  
(7 - 8 May 2026)

 Netherlands

**JUNE**  
2026

**Viral Vector Manufacturing Forum**  
co-located with:  
**Contract Manufacturing Europe**  
(25 - 26 June 2026)

 Germany

**DATE TO BE  
DETERMINED**  
2026

**Biologics Manufacturing SEA 2026**  
(2026)

 Indonesia

**BioFormulate India 2026**  
(2026)

 India

**BioFormulate Asia 2026**  
(2026)

 Singapore

**BioFormulate Korea 2026**  
(2026)

 Korea



**IMAPAC**  
IMAGINE YOUR IMPACT

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL  
INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS

## B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events

"Create an engaging experience for your audiences, explore our B2B Events Solutions."

[LEARN MORE](#)

## 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

"Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector."

[LEARN MORE](#)

## DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

"**Customize the dashboard based on your needs.** Drill down to the data you need using custom views."

[LEARN MORE](#)

## CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

"With access to a database of **60,000+ life science professionals**. We conduct research with a highly -qualified audience."

[LEARN MORE](#)

## REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[LEARN MORE](#)



## Helping the Global Biopharmaceutical Industry Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

